| |
|
|
|
Xtalks, online
2023 -9-29
The future for drug developers is defined by how effectively they adopt innovative pharma R&D strategies and new technologies while navigating industry challenges and complexities.
That’s why the PPD clinical research business of Thermo Fisher Scientific surveyed 150 leaders at biotech and pharmaceutical organizations around the globe to assess trends in drug discovery and development. Respondents shared the therapeutic areas in their pipelines, barriers to bringing drugs to market, innovations that are driving transformation and attitudes toward key topics such as outsourcing, patient recruitment, diversity, decentralized trials and more.
In this webinar, the panel of experts will highlight findings from the pharma R&D report and go beyond the data to explain what they mean for drug developers across the globe. Attendees will hear about the keys to success and prepare to successfully navigate the evolving drug development landscape. In addition, attendees will learn what industry leaders are facing today, and how their outlook on pharmaceutical research and development will influence the industry moving forward.
Join this webinar to get insights into how clinical research professionals are approaching key issues and where the industry is headed.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Matt Latey, VP, Head of Development Operations, Biopharma, PPD, part of Thermo Fisher Scientific Jenny McIlnay, Executive Director Project Management, Peri- and Post-approval Studies and RWE, PPD, part of Thermo Fisher Scientific Tim Peters-Strickland, MD, VP, Global Medical Officer, PPD, part of Thermo Fisher Scientific Anuj Kapadia, VP, Strategy and Corporate Development, PPD, part of Thermo Fisher Scientific
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -9-29
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|